Knowledge, attitudes and practices of the general population towards Marburg virus disease in sub-Saharan African countries: a cross-sectional study.

Background: Marburg virus disease (MVD) is categorized among viral hemorrhagic fevers. MVD is associated with high rates of morbidity and mortality. This study aimed to identify factors affecting MVD knowledge, attitudes and practices in sub-Saharan African countries.

Corroborating written history with ancient DNA: The case of the Well-man described in an Old Norse .

The potential of ancient DNA analyses to provide independent sources of information about events in the historical record remains to be demonstrated. Here we apply palaeogenomic analysis to human remains excavated from a medieval well at the ruins of Sverresborg Castle in central Norway. In , the Old Norse of King Sverre Sigurdsson, one passage details a 1197-CE raid on the castle and mentions a dead man thrown into the well.

Why Is It Too Cold? Towards a Mechanistic Understanding of Cold-Water Pollution Effects on Recruitment of an Imperiled Warmwater Fish.

Environmental temperature shapes the ontogeny of ectotherms by influencing rates of growth and development which can be key determinants of survival. Whereas the escalating impacts of water management on freshwater ecosystems is well documented, the effects of cold-water releases from dams-which can alter downstream temperatures-remains relatively underexplored but may present novel challenges to endemic ectotherms. Specifically, little is known about how thermal depressions reshape phenotypic and genetic patterns during larval metamorphosis for fishes that evolved in warmwater systems.

Enhanced placental antibody transfer efficiency with longer interval between maternal respiratory syncytial virus vaccination and birth.

Background: Respiratory syncytial virus is associated with significant neonatal and infant morbidity and mortality. Maternal bivalent respiratory syncytial virus prefusion F respiratory syncytial virus vaccination to protect neonates and infants was approved in September 2023 for administration between 32+0 and 36+6 weeks to protect neonates and infants. This approved timeframe is narrower than the 24 to 36 week window evaluated in the clinical trial, due to the possible association between preterm birth and vaccine administration.